Specialize in
Love Pharma Holds:
🟧 Investing in proven products that have historic revenue 🟧 Significant short and mid- term growth catalysts. 🟧 Retail ready products for direct, affiliate, referral & licensing. 🟧 6 exclusively licensed technologies 🟧 Experienced team in Pharma & Nutraceuticals
Proven products and nutraceuticals to aid in mental and sexual health and wellness.
CBD AROUSE RX GEL WITH CBD AND/OR THC
A topical gel infused with CBD and/or THC that increases blood flow and sensitivity.
CBD ORAL STRIPS
A discreet cannabis-infused oral strip that speeds-up and enhances the desired effects of CBD.
LOVE Pharma supports all of its products with as much clinical data and research possible.
Supported by a recent human trial that demonstrated a greater than 30% increase in efficacy and speed to performance of THC and CBD.
Clinically proven to increase the number, intensity and speed of orgasm for women.
Love Pharma's FSD supplement is supported by a clinical trial demonstrating an overall reported increase in desire, satisfaction and orgasm within women.
• $150 million Arousal Gel Patented Technology • $50 million Male Enhancement Gel • $7.5 million To Conceive
is focused on maximizing global distribution channels to include Retail brick and mortar, online shops and referral markets.
LOVE Pharma will grow market shares utilizing its patent-protected product portfolio.
Strong public companies that are leading in their respective markets
Canopy Growth Market Cap: $9 Billion Share Price: $22.96 CAD Trading Symbol: TSE:WEE
MindMed Market Cap: $1.28 billion Share Price: $2.92 USD Trading Symbol: MNMD
Ro Market Cap: $308 billion Share Price: 394.80 CHF Trading Symbol: SWX: RO
Stadnyk and Partners Venture Capital previous public company endeavors.
From founding group of Supreme, which was acquired by canopy for $435M in 2021
Market Cap: $32 million CAD Share Price: $1.50 CAD Trading Symbol: TSX: EPRX
Auralief CannaStrip™ Sale Ready
Bloom Arousal Gel Sale ready
Psilocybin Infused Oral Strips
Male Enhancement Cream
To Conceive Gel
(pending regulatory approval)
In the upcoming 12 Months
• Begin Sales of Auralief & Bloom • Launch and commence sales of other exclusively licensed products throughout 2022 and 2023 • Commence research initiative with researchers at Johns Hopkins University in Q4 2022 • Complete development of patented psilocybin oral strip • Complete US markets listing. • Continue looking for M&A opportunities in the pharma and biotech space